Anchor therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach for targeting and allosterically modulating g-protein coupled receptors (gpcrs) on the inside surface of the cell membrane. gpcrs are critically involved in a wide variety of serious illnesses including diabetes inflammation cancer cns disorders and cardiovascular disease.